DoMore Diagnostics and Aarhus University Hospital announce large clinical collaboration on Histotype Px® Colorectal and circulating tumor DNA
OSLO – January 16, 2025 – DoMore Diagnostics, a leader in AI precision medicine for cancer, and Aarhus University Hospital (AUH), ranked as Denmark's best hospital with high ambitions within the field of cancer, announce a research collaboration to clinically assess the prognostic and predictive value of Histotype Px® Colorectal (Histotype Px) digital biomarker alone and in combination with circulating tumor DNA (ctDNA) status in adjuvant chemotherapy (ACT) and ACT-naive stage II and stage III colorectal cancer (CRC) patients.
The primary objective of this study is to independently validate the prognostic ability of Histotype Px® Colorectal in a large cohort, while secondary objectives include comparing its prognostic value with post-operative ctDNA and evaluating whether the combination of Histotype Px and ctDNA outperforms either biomarker used alone. The potential benefit of combining these two biomarkers, particularly in patients with an "uncertain" prognosis, will be explored.
The study cohort consists of 1,290 stage II and stage III CRC patients prospectively recruited from sites in Denmark. ctDNA status is available for all patients. The cohort has an average follow-up period of three years, with complete follow-up data expected in 12 months. The study is well-powered allowing for a reliable comparison between prognostic groups.
“We are very pleased to be working together with DoMore Diagnostics on their novel prognostic and predictive AI biomarker, that analyzes digital images of pathology slides. There is a high medical need to personalize treatment for colorectal cancer patients. We are very excited to see how Histotype Px Colorectal performs in our large Danish cohort with comprehensive ctDNA monitoring, and how it can be used to guide treatment decisions,” said Claus Lingbjerg Andersen, Professor and PI at the Department of Molecular Medicine, Aarhus University Hospital.
Torbjørn Furuseth, MD, CEO and Co-Founder of DoMore Diagnostics said:
"We are excited to collaborate with this group of highly regarded and driven clinical researchers at AUH to validate the performance of Histotype Px in an independent, large-scale cohort of colorectal cancer patients. This study not only reinforces the strength of our AI-driven biomarker in predicting patient outcomes but also explores how combining Histotype Px with ctDNA can provide even more clinically actionable insights. We are committed to advancing personalized medicine and believe that this collaboration will enable better treatment decisions and patient care."
About Aarhus University Hospital
Aarhus University Hospital (AUH) is located in Aarhus, Denmark. The hospital develops and provides highly specialized medical treatment, research and education at an international level. The university hospital's headquarters and main department, known as The New University Hospital, is the largest single hospital in Denmark and one of the largest in Europe. AUH has 10,000 employees, 55 departments and 850 hospital beds. Within Denmark, AUH is the first and largest super-hospital and the highest internationally ranked hospital. AUH has been ranked as Denmark's best hospital 15 times since the independent specialist newspaper of healthcare sector news “Dagens Medicin” started rating the Danish hospitals on quality. This is due to a combination of a high professional level, strong collaborative skills and focus on the individual patient.
AUH has been ranked No. 12 in Newsweek's ranking: World’s Best Smart Hospitals 2024 and hereby the second best in Europe. Aarhus University Hospital is leading in the use of advanced technologies like artificial intelligence (AI), robotic surgery, telemedicine, smart buildings, electronic health records, digital care guide app, etc. According to the Newsweek Ranking, World's Best Hospitals 2024, Aarhus University Hospital is ranked as the 23rd best hospital in the world.
AUH has high ambitions in the field of cancer and started an accreditation process in 2024 to become a Comprehensive Cancer Centre (CCC). The accreditation as a CCC is an important element in the development and strategic ambitions of AUH for improved cancer treatment, efficiency and better use of resources, and transformation of healthcare. Accreditation can also strengthen the reputation of the hospital as a leading cancer hospital, both nationally and internationally.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com